Ferinject, 50mg/ml, 10ml, 1pc

Composition

>

1 ml. solution for intravenous use contains:

Active ingredient:

iron carboximaltosate 50 mg

Pharmacological action

Ferinject is an iron preparation. It is a carboxymaltosate complex of multi-nuclear iron (III) hydroxide.

After parenteral use, the macromolecular complex is captured by the reticulo-endothelial system and breaks down into iron and carboxymaltose.

Iron enters the bloodstream, where it binds to the transport protein transferrin.

Iron in combination with transferrin is transferred to the cells of the body, where it is used for the synthesis of hemoglobin, myoglobin and a large number of enzymes or accumulates in the form of ferritin.

Indications

Iron deficiency anemia occurs when oral iron supplements are ineffective or cannot be used.

The diagnosis must be confirmed by laboratory tests.

Contraindications

• to anemia that are not associated with iron deficiency;
• symptoms of iron overload or impaired iron utilization;
• I trimester of pregnancy;
• children under 14 years of age;
• hypersensitivity to the components of Ferinject.

The drug should be used with caution in patients with liver failure, acute or chronic infectious diseases (possible suppression of erythropoiesis), bronchial asthma, eczema, atopic allergies.

Side effects

Allergic reactions:  often-rash; infrequently-urticaria, hypersensitivity reactions, including anaphylactoid reactions.

Nervous system disorders:  often – headache; dizziness; infrequently-paresthesia.

From the cardiovascular system:  infrequently-a decrease in blood pressure, “flushes” of blood to the skin of the face.

Respiratory system disorders:  rarely-shortness of breath.

From the digestive system:  often – nausea, abdominal pain, diarrhea, constipation; infrequently – change of taste, vomiting, dyspepsia, flatulence.

From the musculoskeletal system:  infrequently – myalgia, back pain, arthralgia.

General reactions:  infrequently – fever, fatigue, chest pain, chills, poor health, peripheral edema.

Local reactions:  often-reactions at the injection site.

From the side of laboratory parameters:  often-an increase in serum ALT, a transient decrease in serum phosphate content; infrequently-an increase in the activity of ACT, GGT, LDH.

How to take, course of use and dosage

Ferinject should be administered intravenously (jet or drip) and by direct injection into the venous section of the dialysis system.

Before opening, the vials should be examined for possible sediment and damage.

You can only use a homogeneous solution without sediment.

Drip use: Ferinject can be administered intravenously in a maximum single dose of up to 20 ml (1000 mg of iron), which should not exceed 0.3 ml (15 mg of iron)/kg of body weight or calculated cumulative dose.

Do not prescribe a drip of Ferinject at a dose of 20 ml more than once a week.

Overdose

Symptoms:  Ferinject in an amount exceeding the body’s needs can cause iron overload, which is manifested by symptoms of hemosiderosis. Determination of iron metabolism indicators such as serum ferritin and transferrin saturation percentage can help in the diagnosis of excessive iron deposition in the body.

Treatment:  conducting symptomatic therapy. If necessary, you can use chelated compounds (for example, deferoxamine).

Form of production

Solution for intravenous use

Storage conditions

At a temperature not exceeding 30 °C, in the original packaging (do not freeze)

Shelf life

3 years

Active ingredient

Iron carboximaltosate

Conditions of release from pharmacies

By prescription

Dosage form

solution for infusions

Description

For adults as directed by your doctor

Indications

Anemia